Sunitinib Plus Gemcitabine Active, Well Tolerated in Aggressive Renal Cell Carcinoma

Share this content:
Combination of antiangiogenic therapy and cytotoxic chemotherapy is active and well tolerated in sarcomatoid and RCC.
Combination of antiangiogenic therapy and cytotoxic chemotherapy is active and well tolerated in sarcomatoid and RCC.

The combination of antiangiogenic therapy and cytotoxic chemotherapy is active and well tolerated in patients with sarcomatoid and poor-risk renal cell carcinoma (RCC), a recent study published online this week in the journal Cancer has shown.

This single-arm, phase 2 trial evaluated the activity of sunitinib and gemcitabine combination in 39 patients with sarcomatoid RCC and 33 patients with poor-risk RCC.

The primary endpoint was objective response rate (ORR), and secondary endpoints were time to progression (TTP), overall survival (OS), safety, and biomarker correlatives. 

Results showed that patients with sarcomatoid RCC and poor-risk RCC had an ORR of 26% and 24%, respectively. Both disease progression and overall survival were slightly higher in patients with poor-risk RCC (TTP=5.5 months; OS=15 months) compared with sarcomatoid RCC (TTP=5 months; OS=10 months).

RELATED: ASPEN Compares Sunitinib, Everolimus in Metastatic Non-Clear Cell Renal Cell Carcinoma

Moreover, patients with greater sarcomatoid histology (>10%) had a higher ORR with stable disease than lower sarcomatoid histology (≤10%) (P=0.04). The common grade ≥3 adverse events reported were neutropenia (n = 20), anemia (n = 10), and fatigue (n = 7).

The study demonstrates that sunitinib and gemcitabine combination shows activity in both sarcomatoid and poor-risk RCC. Additional studies are currently under investigation to see if combination therapy is better than either therapy alone. 

Reference

  1. Michaelson MD, McKay RR, Werner L, et al. Phase II trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015. [Epub ahead of print]. doi: 10.1002/cncr.29503.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters